

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

IN RE APPLICATION OF: <b>Gant et al.</b>	:	
APPLICATION NO.: Not Yet Assigned	:	Examiner: Not Yet Assigned
FILING DATE: Herewith	:	Group Art Unit: Not Assigned
TITLE: SALT FORMS OF 3-(4-BROMO-2,6-DIFLUORO-BENZYLOXY)-5-[3-(4-PYRROLIDIN-1-YL-BUTYL)-UREIDO]-ISOTHIAZOLE-4-CARBOXYLIC ACID AMIDE AND METHOD OF PRODUCTION	:	

---

**BY HAND**

Commissioner for Patents  
BOX PATENT APPLICATION  
Washington, D.C. 20231

Sir:

**PRELIMINARY AMENDMENT**

Prior to examination of the present application on the merits and calculation of the filing fee, applicants request consideration and entry of the following amendments.

Please amend the above-identified application as follows.

**IN THE SPECIFICATION**

On page 1, after the title, please insert the following: --The application claims the benefit of U.S. Provisional Patent Application No. 60/253,513, filed November 28, 2000, which is hereby incorporated by reference in its entirety.--

The above amendment adds no new matter to this application. Applicants respectfully request its entry.

**REMARKS**

Applicants have amended the specification to include priority data as required pursuant 37 C.F.R. §1.78.

Applicants respectfully submit that no new matter is added to the present application.

Applicants have attached hereto a marked-up version of the changes made to the specification by the current amendment. The attached marked-up version is labeled "Version with Markings to Show Changes Made – Do Not Enter ". The marked-up version can be found following the signature page of this Amendment.


A favorable response is requested.

Date:

11/26/2001

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 733-1038

Respectfully submitted,



Adrian G. Looney  
Attorney for Applicants  
Reg. No. 41,406

### In the Specification

- 3 -